http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
-
Gilead Sciences to Present at Upcoming Investor Conference
-
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
-
Gilead Sciences (GILD) and Compugen (CGEN) Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
-
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
-
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
-
Kite (GILD) and Arcellx (ACLX) Expand Strategic Partnership
-
Kite and Arcellx Announce Expansion in Strategic Partnership
-
ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP
-
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
-
Gilead Sciences' (GILD) Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
-
Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer
-
Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS
-
Gilead Sciences (GILD) Presents New Data Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca
-
New Data Presented at EACS 2023 Further Demonstrate Strong Clinical Profile of Twice-Yearly Sunlenca® for Adults With Multi-Drug Resistant HIV
-
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
-
Gilead Sciences (GILD) and Assembly Biosciences (ASMB) Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
-
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
-
Gilead Demonstrates the Impact of Global Collaboration in Advancing HIV Research and Health Equity at EACS 2023
-
Gilead Sciences to Release Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
-
Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
-
Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders
-
Gilead Sciences (GILD) Announces CHMP Adopts Positive Opinion to Extend the Use of Veklury to Treat COVID-19 in People With Hepatic Impairment
-
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment
-
Gilead Sciences (GILD) Announces FDA Approval of Veklur to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
-
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
-
Gilead Sciences to Present at Upcoming Investor Conferences
-
Gilead Sciences (GILD) Announces Partial Clinical Hold for Magrolimab Studies in AML
-
Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML
-
Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
-
Gilead Sciences (GILD) and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
-
Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation
-
Ligand Reports Second Quarter 2023 Financial Results
-
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
-
Gilead Sciences (GILD) Announces EU Approval of Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer
-
Gilead Sciences (GILD) Reports Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
-
Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV
-
Gilead Sciences (GILD) To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
-
New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic
-
Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities
-
Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS
-
Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S.
-
Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023
-
Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023
-
Gilead Sciences (GILD) Announces FDA Approval of Veklury for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
-
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
-
Gilead Sciences (GILD) Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
